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Abstract 
The anaphylatoxic peptide CSa is an important inflammatory mediator of the complement system. We have generated human CSa-receptor (hC5aR) 
mutants with truncation of its cytosolic carboxyl-terminus (C-terminus). Both mutants were analysed for CSa-binding in transiently expressing COS 
cells, and one mutant additionally for GTP-binding regulatory protein (G-protein) coupling in cRNA-injected Xenopus oocytes. Our data suggest 
that (a) amino acids (aa) 314 to 326 as part of the C-terminus are necessary for proper receptor folding or expression and (b) the receptor C-terminus 
distal from position 327 is not critical for receptor expression, folding, binding and G-protein coupling. 
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1. Introduction 
The anaphylatoxic peptide C5a as part of the comple- 
ment system is an important mediator of inflammatory 
reactions. It causes chemotaxis, activation of neutro- 
phils, smooth muscle contraction and an increase in vas- 
cular permeability. After generation by proteolytic cleav- 
age of native C5, the anaphylatoxin can interact with its 
specific receptor, described on several cells like neutro- 
phils, eosinophils, and dibutyryl-CAMP-differentiated 
U937 or HL-60 cells (for a review see [l-3]). The hC5aR 
was recently cloned from these two cell-lines [4,5]. Its 
identity was confirmed by specific ligand-binding and 
various functional assays [4-6]. Recently we reported the 
cloning and functional expression of the recombinant 
hC5aR in Xenopus oocytes and demonstrated its abso- 
lute dependence on an additional human factor for func- 
tional expression [7]. In this paper we have analysed 
deletion mutants of the hC5aR truncated after aa-posi- 
tion 326 (tr326) and 313 (tr313), respectively, for ligand- 
binding in transfected COS cells. After in vitro transcrip- 
tion, we have investigated mutant tr326 for G-protein 
coupling as CSa-induced whole cell current in cRNA- 
microinjected Xenopus laevis oocytes. 
2. Materials and methods 
2.1. Chemicals and enzymes 
Oligonucleotides for PCR and all sequencing primers were synthe- 
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sized on a GENE Assembler Plus (Pharmacia) and purified according 
to manufacturer’s instructions. Restriction endonucleases were ob- 
tained from Pharmacia, deoxynucleotide-triphosphate solutions from 
Gibco. All other materials were obtained from Sigma if not otherwise 
indicated. 
2.2. Genetic onstructions 
As previously described the coding sequence for the hC5aR was 
recloned by PCR from genomic DNA of peripheral blood leukocytes 
into the Hind111 site of the pCDM8 (Invitrogen) generating plasmid 
pCC1 [7]. This wild-type construct was taken as PCR-template using 
(1) the original primer for the S-end (TGT AGA ATT CAA GCT TAG 
CCC AGG AGA CGA G), and (2a) a reverse anti-sense 3’-end primer 
consisting of part of the hC5aR sequence and an additional STOP- 
don (bold) behind the nucleotides corresponding to aa position 3 13 
(CTA GTC AGC AAG C7’T CTA TTT CCG CAG TCG GCC CTG), 
or (2b) corresponding to aa position 326 (GAA TTC AAG CTT CTA 
CTC TTC AGT CAA CAC GTT), respectively. Additionally, all prim- 
ers contained a Hind111 cloning site (italics) for convenient subcloning. 
Amplification was performed at an annealing temperature of 50°C in 
30 cycles using Taq polymerase (Boehringer) according to the manufac- 
turer’s instructions. After digestion with Hind111 the PCR fragment was 
subcloned into the eucaryotic expression vector pCDM8, also suitable 
for in-vitro transcription, and amplified in the E. coli strain XSl27/p3 
(Invitrogen). Positive clones were completely sequenced using the T7 
sequencing kit (Promega). Plasmid preparations for transfection and in 
vitro transcription were prepared by a commercial kit (Qiagen) accord- 
ing to the manufacturer’s specifications. 
2.3. Cell culture conditions and transient ransfection i  COS.M6 cells 
COS.M6 cells (ATCC) were grown at 37°C in a humidified atmos- 
phere with 5% CO2 in DMEM (Gibco BRL) medium supplemented 
with 10% heat-inactivated fetal calf serum, 2 mM glutamine, and pen- 
icillin (50 U/ml)/streptomycin (5O@ml). COS cells were transfected by 
the DEAE-Dextran method with slight modifications: 1 x 10’ cells at- 
tached to a 175 cm*-cell culture flask were incubated with a solution 
containing among others [8,9] 10 pug plasmid DNA, 188 &ml DEAE- 
Dextran (Sigma) and 100 PM chloroquin. After 4 h this solution was 
removed and cells were shocked with 10% DMSO-PBS for 2 min. After 
2 x washing with PBS cells were incubated for 48 h with supplemented 
DMEM and harvested with EDTA-PBS (2 mM) solution for further 
analyses in binding studies. 
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2.4. Purity of the stimulus recombinant human C5a (rhC5a) 
For radiolabeling commercially available rhC5a was used (Sigma). 
For all other purposes rhC5a was prepared and analysed from our own 
E. coli strain as described previously [lo]. 
2.5. [“‘I]C5a binding studies 
Radiolabellina of C5a: iodination of recombinant C5a (Sigma) was 
performed as d&cribed previously [ll]. The recovery of biologically 
active peptide was approx. 15% for [?]rhC5a as assayed by the ATP- 
release assay with guinea-pig platelets [11,12]. The average specific 
activity obtained was 1700 Ci/mmol [‘251]rhC5a. 
For-binding kinetics 1 ml of a cell suspension was prepared in HBSS 
buffer at 4’C. 22°C. and 37°C. The experiment was started by the 
addition of [r’I]rhC5a. At different time points three aliquots of 45 ~1 
(0.79 nM [“‘I]rhC5a equivalent o 10,500 cpm per aliquot) were re- 
moved to determine bound radioactivity by separation of free and 
cell-bound [“‘I]rhCSa through a sucrose cushion as described [13]. 
For competitive binding studies a mixture 30 ~1 of 0.09 nM 
[‘*‘I]rhC5a was mixed with 90 ~1 of cell suspension. After 30 min at 
22°C three aliquots of 45 were removed and bound radioactivity was 
determined as described above [l 11. Iterative curve fitting of the binding 
data was performed on the bases of one and two-site models using 
LIGAND [14]. 
2.6. Preparation of cRNA 
cRNA for the human hC5aR and receptor mutant tr326 were pre- 
pared from the T7 promoter of the linearized (XbaI) pCDM8-receptor 
constructs using the mCAP mRNA capping kit (Stratagene). cRNA 
was quantitated by densitometric evaluation from ethidium bromide- 
stained agarose gels against a known RNA standard using the CS-1 
system (Cybertech). To supply the cells with the mRNA for the addi- 
tional yet uncharacterized human factor [7] total RNA of non-differen- 
tiated U937 cells (ATCC) grown in RPM1 1640 medium, (Gibco) sup- 
plemented as described for DMEM medium, was prepared by the 
guanidinium isothiocyanate method [15] and stored at -70°C in water. 
2.7. Oocyte expression experiments 
Preparation of defolliculated Xenopus laevis oocytes (Kiihler, Ham- 
burg, Germany) and electrophysiological recordings were performed as 
described nreviouslv 171.46 nl RNA per oocvte corresponding to 23 ng 
cRNA and 23 ng total RNA of non-differentiated U937 &ls, were 
injected by a motor-driven microinjector (Drummond) through glass 
capillaries broken to an outer diameter of 12-25 ,um. Two days later 
functional activity was tested by current recording of voltage-clamped 
oocytes (-70 mV) exposed to frog Ringer solution (ND96) containing 
20 nM rhC5a. 
3. Results 
3.1. [‘Z51JrhC.5a binding-studies 
3.1.1. Kinetics and temperature-dependence of 
[‘251]rhC5a binding. First binding kinetics were per- 
formed at 4°C 22°C and 37°C. Binding equilibrium 
was achieved best at 22°C after 30 min (data not shown), 
and all further competitive binding studies were per- 
formed at these conditions. 
3.1.2. Competitive binding studies. The specific C5a- 
binding sites of wild-type hC5aR and the both receptor 
mutants were analysed in transfected COS.M6 cells 
using a constant concentration of [lz51]rhC5a nd in- 
creasing concentrations (in triplicates) of unlabeled 
rhC5a (Fig. 1). The data of three independent binding- 
experiments were analysed by iterative curve fitting to 
one- and two-site models: for the wild-type hC5aR we 
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Fig. 1. One representative competitive binding study of COS.M6-cells 
(1 x lO’/ml), transiently transfected with pCDM8-tr326 (o), pCDM8- 
tr313 (v), pCDM8 without insert (0) (n = 3). A constant concentration 
of [‘*‘I]rhCSa was displaced by increasing concentrations of rhC5a. A 
total of 14,800 cpm per sample was used. Binding parameters were 
calculated by iterative curve fitting from three such experiments. 
could detect 370,000 & 160,000 receptors/cell with a dis- 
sociation constant (KJ of 7.0 ? 0.4 (nM). For tr326 we 
found 70,000 receptors/cell with a Kd of 6.0 f 2.1 (nM). 
In contrast, no specific binding for the transfected recep- 
tor-mutant tr313 could be detected, in comparison to 
COS cells transfected with pCDM8 vector alone (Fig. 1). 
3.2. Oocyte expression experiments 
To analyse the receptor mutant tr326 for functional 
G-protein coupling we microinjected Xenopus laevis 
oocytes with in vitro transcribed cRNA of hC5aR wild 
type and mutant tr326 and determined whole cell current 
during stimulation with 20 nM rhC5a. Mutant tr313 was 
not further analysed. The experiment was performed in 
duplicate. Fig. 2 depicts representative responses for 
oocytes microinjected with mRNA/cRNA (a) without 
receptor construct, (b) with wild type receptor, and (c) 
with mutant tr326. In one experiment all 5 tr326 injected 
oocytes showed positive responses with maximal cur- 
rents between 50 and 100 nA. In a second independent 
experiment 5 out of 6 tr326-oocytes responded with max- 
imal currents between 35 and 75 nA. Oocytes without 
receptor did not respond (n > 10) whereas wild type- 
injected oocytes as positive-controls (n = 3) showed max- 
imal currents between 100 and 250 nA. 
4. Discussion 
The hC5aR is thought to belong to the family of G- 
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Fig. 2. Representative whole cell currents determined by voltage 
clamped Xenopus laevis oocytes microinjected with supplementing fac- 
tor plus: (a) dH,O, (b) cRNA from in-vitro transcribed hC5aR wild 
type, and (c) cRNA from tr326. The oocytes were stimulated with 
20 nM rhC5a (J) for 1 min (I). 
protein coupled receptors with 7 membrane-spanning 
regions, an extracellular amino- and an intracellular car- 
boxyl-terminus. Beside its homology to members of these 
family and the prediction of 7 a-helical hydrophobic 
putative transmembranous regions, broad experimental 
evidence has accumulated for this assumption: pertussis- 
toxin sensitivity of CSa-response [l&18], CSa-dependent 
guanosine 5’-0(3_thiotriphosphate (GTPyS)-binding [6], 
co-purification of receptor and G-protein [19], and co- 
transfection experiments with hC5aR and G-a,, [20,21]. 
For other receptors of this family, in particular the 
adrenergic receptors, there exists a thorough under- 
standing of structure/function relationship using cells 
transfected with mutants of these receptors for func- 
tional studies: simplified, transmembranous regions and/ 
or extracellular parts of the receptor seem to be involved 
in ligand binding, whereas the intracellular loops and 
part of the cytosolic C-terminus are described as impor- 
tant for G-protein coupling (for a review see [22]). 
Up to now only limited information is available about 
structure/function relationship for the hCSaR, which 
only concerns the extracellular N-terminus and its in- 
volvement in ligand binding [23,24]. Thus far no data 
have been published obtained with recombinant hC5aR 
mutants, except for one article concerning hCSaR/ 
human formyl peptide receptor (hFMLP-R) chimeras 
which were only assayed for the specific binding of 
formyl peptides but not for the ligand C5a [25]. We have 
analysed two mutants of the hC5aR with deleted intra- 
cellular C-terminus for ligand-binding in transiently 
transfected COS-cells. The C-terminal end of the last 
membrane-spanning segment of the hC5aR is predicted 
for aa 302 (PC-GEN-Software, [26,27]) or 305, respec- 
tively [28]. The one-deletion mutant, tr326, showed an 
essentially unchanged Kd compared to the wild type re- 
ceptor, in good agreement with data obtained with 
rhC5aR-transfected COS-cells by others (1.4 nM [4]); 
1.5-2 nM = &-high ahity and 20-25 nM = &_iow sanity [5]). 
Mutant tr326 was further analysed for functional G- 
protein coupling as measured by rhC5a-inducable whole 
cell current in Xenopus oocytes after microinjection of 
cRNA. We found essentially the same response for this 
mutant and the wild type receptor with a tendency to 
lower amplitudes of the current for the mutant. This 
observation matches with the lower receptor number 
found in the binding studies with tr326-transfected COS- 
cells. These differences could be due to decreased recep- 
tor-expression or -stability of this mutant. The other 
more complete deletion mutant tr313 did not show any 
specific [‘*‘I]rhC5a binding. We conclude that (a) aa 314 
to 326 as part of the C-terminus are necessary for proper 
receptor folding or expression, and (b) that the receptor 
C-terminus distal from position 327 is not critical for 
expression, folding, binding and G-protein coupling. To 
our knowledge, only a few such truncations of other 
G-protein coupled receptors have been studied before: 
the /?*-adrenergic receptor [29] as the classical example, 
and recently the luteinizing hormone receptor [30], gas- 
trin-releasing peptide receptor [3 l] and thyrotropin-re- 
leasing hormone receptor [32] giving similar evidence 
that the distal C-terminus is not essential for G-protein 
coupling. 
So far, the most related cloned receptor to the hC5aR 
is the hFMLP-R, also a chemoattractant factor receptor, 
with a 34% sequence homology [33] which similarly cou- 
ples to a Pertussis toxin sensitive G-protein using similar 
signal-transduction pathways [6,34]. For the hFMLP-R 
it was demonstrated by point mutations that the third 
cytosolic loop, contrary to other receptors, does not play 
a critical role in the functional coupling to G-proteins 
[35]. Recently Bommakanti et al. showed that only one 
site-specific synthetic peptide representing part of the 
cytosolic hFMLP-R C-terminus (aa position 322-336 of 
350) competed with its receptor for binding of bovine Gi, 
whereas peptides representing the intracellular loops II 
and III failed [36]. Assuming a similar signal transduc- 
tion mechanism for the hC5aR one might propose the 
proximal part of the hCSaR-R cytosolic C-terminus (aa 
302-326) as being important for G-protein coupling. 
Additionally, for future studies it is valuable to know 
that mutant tr326 shows essentially normal CSa-ligand- 
binding and G-protein coupling because it can now be 
considered as a good candidate for future desensitization 
or phosphorylation analysis: This mutant is lacking al- 
most all serines and threonines of the cytosolic receptor 
C-terminus which are discussed as being involved in the 
recently demonstrated fast receptor desensitization (de- 
tectable as CSa-induced decrease in [32P]y-GTP binding 
in transfected RBL.2H3 cells) and phosphorylation by a 
proposed ‘/?-adrenergic receptor-kinase-like’ receptor ki- 
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nase [6,37,38], (for review of /?-adrenergic receptor-ki- 
nase function see [22]). 
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